Pharmaceutical Industry R&D Partnering Strategies By Riccardo Pigliucci Drug Discovery With a sustained rate of more than 250 R&D partnering deals each year many valuable lessons are being learned. Although there is no exact 'formula for success' there are many 'success factors' that can be utilised to reduce the risk… Read More
Increasing the chances of lead discovery By Sandra Fox, MBA, Dr Helen Wang, Dr Lynne Sopchak and Dr Richard Khoury For HTS laboratories worldwide, the mission is to supply therapeutic groups in the shortest time possible with high quality hits and leads that will become drug candidates. Mounting pressure to… Read More
The Genie in the Test Tube - From Gene to Gene Therapy: Part 2 By Dr Jan Steiner In the previous edition, we discussed gene therapy in terms of potential vectors and their applications. Now, we discuss the potential clinical uses of these constructs. To date, the main applications of… Read More
The promise of pharmacogenetics and pharmacogenomics By Dr Tim Peakman and Dr Steve Arlington Within the next 10 years the benefits of pharmacogenetics and pharmacogenomics will inevitably outweigh the disadvantages. But what are the commercial and legal implications for the pharmaceutical industry especially for companies who have lead candidates ready… Read More
The Integration Abyss By Dr Scott D. Kahn The long-standing disconnect between target discovery/characterisation and compound discovery is a major challenge facing the pharmaceutical industry in its quest to develop innovative therapies from the wealth of information flowing from the human genome. There is enormous interest within the pharmaceutical and… Read More
Discovery Research in the Co-Genomic Era - Biology goes industrial By Dr Timothy Wells and Dr Georg Feger The parallel between the search for gold in the last century and drug discovery in the co-genome era is very clear. As with all gold rushes the rewards will go to the… Read More
Do venture capitalists act as gatekeepers of new technology? By Dr June Grindley and Samantha Smart This article discusses the important role that venture capitalists and others play in helping to create companies around new technologies. We asked a number of venture capitalists, when considering funding a new company, what… Read More
High-throughput Crystallisation By Dr Sara Moran and Dr Lance Stewart With structure-based drug design on the increase can the development of high-throughput crystallisation fulfil its promise to revolutionise the drug discovery process? In an era when the development of drugs is hindered by the exorbitant costs of discovery and clinical… Read More
The Industrialisation of Bioinformatics By Dr Alex Titomirov With the completion of the ‘draft’ sequence of the human genome predicting an estimate of 40,000-120,000 genes that describe us, the real work begins. The problem now is not lack of data but lack of tools to thoroughly analyse what we already… Read More
By Dr David C. U’Prichard It is almost axiomatic that the pharmaceutical R&D industry has not achieved in the last decade an increase in productivity (measured as high value NCEs) commensurate with the explosion of new biological information, chemistry techniques and information storage/retrieval/examination systems, let alone the real increase in… Read More
The role of toxicogenomics in drug discovery By Dr Robin E. Neft and Dr Spencer Farr The information that toxicogenomics can bring in terms of toxic mechanisms, safety and efficacy must ultimately have a major impact on the drug discovery process. Large scale genome sequencing has lead to elucidation of… Read More
By Dr Ashok R. Dongre and Dr Stanley A. Hefta The genomic sequencing efforts spawned the field of proteomics by providing the basic blueprint for protein sequences, enabling proteomics to become the contemporary technology for studying the underlying mechanisms of disease. This review will address the technologies related to proteomic… Read More
The Genie in the Test Tube - From Gene to Gene Therapy: Part 1 By Dr Jan Steiner For thousands of years, medicine was a descriptive art, with treatments for disease arising from astute observation and trial and error. The rise of modern forms of biological sciences, especially the developments… Read More
Emerging therapeutic vaccines By Marc Hertz, Soren Mouritsen and Anand Gautam The excitement over the past 30 years for immunotherapy of cancer and other diseases has not led to the expected clinical successes. Over-enthusiasts predicted a cure for cancer with the initial development of monoclonal antibody technology, and later the… Read More
By Matthias Mann, Protein Interaction Laboratory (PIL), University of Southern Denmark Affinity proteomic methods can translate genomic data into validated targets for drug discovery. Baits such as tagged gene product or small molecules obtained from cell-based assays are used to purify interacting proteins. These proteins are then identified by high… Read More
Using Expression Databases for Drug Discovery By Dr Greg Lennon Reference databases are being built cataloguing the amount of RNA each gene makes under different conditions and in different individuals. These databases can be mined easily and effectively to aid the drug discovery process. The success of the Human Genome… Read More